Real-World Study of Lanreotide Autogel in Routine Practice in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Hong Kong and Taiwan
Lanreotide autogel was well tolerated and showed good tumor control rate in a real-world setting. These findings align with results from previous studies in Caucasian, Japanese, and Korean patients, thus supporting lanreotide autogel for treating patients with GEP-NETs of Chinese ethnicity.
Authors
- Li‐Yuan Bai (ORCID: https://orcid.org/0000-0001-7739-4077)
- Aude Houchard (ORCID: https://orcid.org/0000-0001-6248-8986)
- Stephen L. Chan (ORCID: https://orcid.org/0000-0001-8998-5480)
- Hsiao-Hsiang Cheng
- Jen‐Shi Chen (ORCID: https://orcid.org/0000-0001-9756-3974)
- Xuan-Mai Truong-Thanh
- Ming‐Huang Chen (ORCID: https://orcid.org/0000-0003-3187-7393)
- Xiaofeng Shi
- Ji-Yan Zou
Institutions
- Chang Gung University (TW)
- Chinese University of Hong Kong (HK)
- Ipsen (France) (FR)
- China Medical University (TW)
- Taipei Veterans General Hospital (TW)
- Prince of Wales Hospital (CN)
- Linkou Chang Gung Memorial Hospital (TW)
- China Medical University Hospital (TW)
- Koo Foundation Sun Yat-Sen Cancer Center (TW)
Publication Details
- Journal
- Oncology and Therapy
- Published
- 2024-08-31
- DOI
- https://doi.org/10.1007/s40487-024-00302-6
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Ipsen